Abstract:Colorectal cancer (CRC) is one of the most common malignancies worldwide. Given its insidious onset, the condition often already progresses to advanced stage when symptoms occur. Thus, early diagnosis is of great significance for timely clinical intervention, efficacy enhancement, and prognostic improvement. Featuring high throughput, fastness, and rich information, next generation sequencing (NGS) can greatly shorten the detection time, which is a widely used detection technique at present. To screen specific genes or gene combinations in fecal DNA that are suitable for diagnosis and prognostic prediction of CRC, and to establish a technological platform for CRC screening, diagnosis, and efficacy monitoring through fecal DNA detection. NGS was used to sequence the stool DNA of patients with CRC, which were then compared with the genetic testing results of the stool samples of normal controls and patients with benign intestinal disease, as well as the tumor tissues of CRC patients. Specific genes or gene combinations in fecal DNA suitable for diagnosis and prognostic prediction of CRC were screened, and their significances in diagnosing CRC and predicting patients' prognosis were comprehensively evaluated. High mutation frequencies of , and were detected in the stools and tumor tissues of CRC patients prior to surgery. Contrastively, no pathogenic mutations of the above three genes were noted in the postoperative stools, the normal controls, or the benign intestinal disease group. This indicates that tumor-specific DNA was detectable in the preoperative stools of CRC patients. The preoperative fecal expression of tumor-associated genes can reflect the gene mutations in tumor tissues to some extent. Compared to the postoperative stools and the stools in the two control groups, the pathogenic mutation frequencies of and were significantly higher for the preoperative stools ( 7.328, < 0.05; 4.219, 0.05), so further analysis with larger sample size is required. Among CRC patients, the pathogenic mutation sites of occurred in 16 of 27 preoperative stools, with a true positive rate of 59.26%, while the pathogenic mutation sites of occurred in 10 stools, with a true positive rate of 37.04%. The sensitivity and negative predictive values of the combined genetic testing of and were 66.67% (18/27) and 68.97%, respectively, both of which were higher than those of or mutation detection alone, suggesting that the combined genetic testing can improve the CRC detection rate. The mutation sites exon 4 A84G and exon 20 I821T (mutation start and stop positions were both 7579436 for the former, while 55249164 for the latter) were found in the preoperative stools and tumor tissues. These "undetected" mutation sites may be new types of mutations occurring during the CRC carcinogenesis and progression, which needs to be confirmed through further research. Some mutations of "unknown clinical significance" were found in such genes as , , , , , and , whose clinical values is worthy of further exploration. NGS-based fecal genetic testing can be used as a complementary technique for the CRC diagnosis. Fecal and can be used as specific genes for the screening, diagnosis, prognostic prediction, and recurrence monitoring of CRC. Moreover, the combined testing of and genes can improve the CRC detection rate.

Performance Validation of an Amplicon-Based Targeted Next-Generation Sequencing Assay and Mutation Profiling of 648 Chinese Colorectal Cancer Patients.

Performance Study of an Amplification-Based NGS Test on Clinical FFPE Specimens in China's First Multi-Center Study.

Correlation between NGS panel-based mutation results and clinical information in colorectal cancer patients

Validating a Targeted Next-Generation Sequencing Assay and Profiling Somatic Variants in Chinese Non-Small Cell Lung Cancer Patients

Feasibility of Amplicon-Based Targeted Next-Generation Sequencing of Colorectal Cancer in Endoscopic Biopsies

NGS-based Oncogenic Mutations Analysis in Advanced Colorectal Cancer Patients Improves Targeted Therapy Prediction.

Whole Exome Sequencing Of Ulcerative Colitis-Associated Colorectal Cancer Based On Novel Somatic Mutations Identified In Chinese Patients

Fecal gene detection based on next generation sequencing for colorectal cancer diagnosis.

Evaluation of Liquid Biopsies for Molecular Profiling in Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC): What Happens after Panel Testing by Next Generation Sequencing (NGS)?

Molecular Characterization and Prognostic Analysis of Non-Small Cell Lung Cancer: A Single Centric Real-World Study.

Validation of Targeted Next-Generation Sequencing for RAS Mutation Detection in FFPE Colorectal Cancer Tissues: Comparison with Sanger Sequencing and ARMS-Scorpion Real-Time PCR.

Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients

P2.15-33 Evaluation of Liquid Biopsies for Molecular Profiling in Patients (pts) with Advanced NSCLC: What Happens after Panel Testing by NGS?

Comprehensive genomic profiling reveals prognostic signatures and insights into the molecular landscape of colorectal cancer

Assessment of the Clinical Application of Detecting EGFR, KRAS, PIK3CA and BRAF Mutations in Patients with Non-Small Cell Lung Cancer Using Next-Generation Sequencing

Genomic Alterations and Clinical Characterization in Chinese Patients with Metastatic Colorectal Cancer

Molecular Profiling of Patients (pts) with Advanced Colorectal Cancer (CRC): Princess Margaret Cancer Center Experience.

An Accurate And Comprehensive Clinical Sequencing Assay For Cancer Targeted And Immunotherapies

Gene Mutation Profiling in Chinese Colorectal Cancer Patients and Its Association with Clinicopathological Characteristics and Prognosis

Clinical Validation of an NGS-based Assay for Detecting Multiple Genomic Alterations in Chinese Patients with Non-Small Cell Lung Cancer

Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients